1. Home
  2. ARQT vs ATRC Comparison

ARQT vs ATRC Comparison

Compare ARQT & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$28.85

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Logo AtriCure Inc.

ATRC

AtriCure Inc.

HOLD

Current Price

$39.22

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARQT
ATRC
Founded
2016
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
1.6B
IPO Year
2020
2005

Fundamental Metrics

Financial Performance
Metric
ARQT
ATRC
Price
$28.85
$39.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
9
Target Price
$24.83
$52.22
AVG Volume (30 Days)
1.8M
450.9K
Earning Date
10-28-2025
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$317,929,000.00
$518,304,999.00
Revenue This Year
$85.51
$16.90
Revenue Next Year
$30.74
$12.25
P/E Ratio
N/A
N/A
Revenue Growth
129.21
15.80
52 Week Low
$11.13
$28.29
52 Week High
$31.77
$43.11

Technical Indicators

Market Signals
Indicator
ARQT
ATRC
Relative Strength Index (RSI) 52.58 50.78
Support Level $27.71 $40.11
Resistance Level $30.26 $41.33
Average True Range (ATR) 1.06 1.10
MACD -0.24 -0.37
Stochastic Oscillator 49.91 16.07

Price Performance

Historical Comparison
ARQT
ATRC

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

About ATRC AtriCure Inc.

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

Share on Social Networks: